Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening)

被引:0
作者
Esmeralda Núñez Cuadros
Joan Calzada-Hernández
Daniel Clemente
Sara Guillén Martín
Laura Fernández Silveira
María José Lirola-Cruz
Alfredo Tagarro
Marisol Camacho Lovillo
Rosa María Alcobendas Rueda
Agustín López López
Miren Satrustegi Aritziturri
Cristina Calvo
机构
[1] UGC Pediatría,Pediatric Rheumatology Unit
[2] Hospital Regional Universitario de Málaga,Unitat de Reumatologia Pediàtrica, Servei de Pediatria
[3] Instituto de Investigación Biomédica de Málaga (IBIMA),Pediatric Rheumatology Unit
[4] Hospital Sant Joan de Déu,Department of Paediatrics
[5] Hospital Infantil Universitario,Servicio de Inmunología
[6] Niño Jesús,Department of Paediatríc Rheumatology
[7] Hospital Universitario de Getafe,Pediatrics Department, Instituto de Investigación 12 de Octubre (imas12)
[8] CIBERINFEC ISCIII,Department of Pediatric Rheumatology
[9] Getafe,Department of Paediatrics
[10] Reumatología e Infectología Pediátricas,Servicio de Pediatría
[11] Hospital Universitario Virgen del Rocío,Department of Pediatrics, Infectious and Tropical Diseases
[12] Instituto Hispalense de Pediatría,undefined
[13] Hospital Universitario Infanta Sofía,undefined
[14] Universidad Europea,undefined
[15] La Paz Children’s Hospital,undefined
[16] Hospital Universitario Puerta de Hierro,undefined
[17] Hospital Universitario Donostia,undefined
[18] Hospital Universitario La Paz,undefined
[19] and La Paz Research Institute (IdiPaz). CIBERINFEC. ISCIII,undefined
[20] Translational Research Network of Pediatric Infectious Diseases (RITIP),undefined
来源
European Journal of Pediatrics | 2022年 / 181卷
关键词
Infections; Screening; Prophylaxis; Vaccination; Immune-mediated rheumatic diseases; Consensus;
D O I
暂无
中图分类号
学科分类号
摘要
This study provides practical recommendations on infection screening in pediatric patients with immune-mediated rheumatic diseases and immunosuppressive therapies. For this reason, a qualitative approach was applied. A narrative literature review was performed via Medline. Primary searches were conducted using Mesh and free texts to identify articles that analyzed data on infections and vaccinations in pediatric patients with immune-mediated rheumatic diseases and immunosuppressive therapies. The results were presented and discussed in a nominal group meeting, comprising a committee of 12 pediatric rheumatologists from the infections prevention and treatment working group of the Spanish Society of Pediatric Rheumatology. Several recommendations were generated. A consensus procedure was implemented via a Delphi process that was extended to members of the Spanish Society of Pediatric Rheumatology and Vaccine Advisory Committee of the Spanish Association of Pediatrics. Participants to the process produced a score ranging from 0 = totally disagree to 10 = totally agree. Agreement was considered if at least 70% of participants voted ≥ 7. The literature review included more than 400 articles. Overall, 63 recommendations were generated (21 on infection screening) voted by 59 pediatric rheumatologists and other pediatric specialists, all of them achieving the pre-established agreement level. The recommendations on screening cover all the procedures (serology, assessment of risk factors, and other clinical activities) connected with the screening for infections including tuberculosis; hepatitis A, B, and C viruses; measles; mumps; rubella; diphtheria; and other infections. 
引用
收藏
页码:2343 / 2354
页数:11
相关论文
共 269 条
[1]  
Furer V(2019)Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD RMD Open 5 751-762
[2]  
Rondaan C(2021)Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry Rheumatol Int 41 e486-e492
[3]  
Heijstek M(2013)Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population J Crohns Colitis 7 1884-1894
[4]  
van Assen S(2009)Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis Rheum 60 1185-1206
[5]  
Bijl M(2010)The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Eur Respir J 36 620-622
[6]  
Agmon-Levin N(2007)Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy Swiss Med Wkly 137 247-253
[7]  
Thiele F(2006)Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience Acta Reumatol Port 31 2122-2127
[8]  
Klein A(2003)Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis Rheum 48 1766-1772
[9]  
Windschall D(2005)Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 36-45
[10]  
Hospach A(2016)Consensus document on prevention and treatment of tuberculosis in patients for biological treatment Arch Bronconeumol 52 2102-2108